NCT03884465 - Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

December 23, 2020

Study Completion Date

December 23, 2020

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Inhaled dry powder treprostinil (LIQ861)

Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.

Trial Locations (3)

35392

Studienambulanz fur Pulmonale Hypertonie at Medizinishe Klinik II, Universitatskinikum Giessen und Marburg GmbH, Giessen

54500

CHRU de Nancy, Nancy

94270

CHU de Bicetre, Le Kremlin-Bicêtre